Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ME3113 (udenafil) vs placebo in benign prostatic hyperplasia with lower urinary tract symptoms (Phase II)
jRCT2080222623Phase 2
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in benign prostatic hyperplasia (BPH) comparing ME3113 (udenafil) with Placebo (2 arms).
02
Drugs
udenafil
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on jRCT2080222623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222623.